Lack of a significant drug interaction between raltegravir and tenofovir

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3253-3258

  Wenning, Larissa A ^a,c   Friedman, Evan J ^a   Kost, James T ^a   Breidinger, Sheila A ^a   Stek, Jon E ^a   Lasseter, Kenneth C ^b   Gottesdiener, Keith M ^a   Chen, Joshua ^a   Teppler, Hedy ^a   Wagner, John A ^a   Stone, Julie A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PharmaNet Development Group Inc   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; PLACEBO; RALTEGRAVIR; TENOFOVIR DISOPROXIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MONOTHERAPY; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 50949095712     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00005-08     Document Type: Article

References (24)

1. Asante-Appiah, E., and A. M. Skalka. 1999. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res.52:351-369.
2. Chittick, G. E., J. Zong, M. R. Blum, J. J. Sorbel, J. A. Begley, N. Adda, and B. P. Kearney. 2006. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob. Agents Chemother. 50:1304-1310.
3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC.
4. Droste, J. A. H., C. P. W. G. M. Vevweij-van Wissen, B. P. Kearney, R. Buffels, P. J. vanHorssen, Y. A. Hekster, and D. M. Burger. 2005. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. 49:680-684.
5. Esposito, D., and R. Craigie. 1999. HIV integrase structure and function. Adv. Virus Res. 52:319-333.
6. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, and R. D. Isaacs. 2006. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, abstr. 159LB. 13th Conf. Retrovir. Opportunistic Infect., Denver, CO.
7. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2006. Potent efficacy of Mk-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus: 24-week data, abstr. H-1670b, p. 195. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. (Final program.)
8. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
9. Hammer, S. M., M. S. Saag, M. Schechter, J. S. Montaner, R. T. Schooley, D. M. Jacobsen, M. A. Thompson, C. C. Carpenter, M. A. Fischl, B. G. Gazzard, J. M. Gatell, M. S. Hirsch, D. A. Katzenstein, D. D. Richman, S. Vella, P. G. Yeni, and P. A. Volberding. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 296:827-843.
10. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
11. Kassahun, K., I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, and L. A. Wenning. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663.
12. Kearney, B. P., J. R. Sayre, J. F. Flaherty, S. S. Chen, S. Kaul, and A. K. Cheng. 2005. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J. Clin. Pharmacol. 45:1360-1367.
13. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
14. Markowitz, M., B. Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H.Wan, M. D. Miller, L. A. Wenning, and H. Teppler. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection. Results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
15. Markowitz, M., J. O. Morales-Ramirez, B. Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, and H. Teppler. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
16. Merschman, S. A., P. T. Vallano, L. A. Wenning, B. K. Matuszewski, and E. J. Woolf. 2007. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B 857:15-19.
17. O'Brien, M. E., R. A. Clark, C. L. Besch, L. Myers, and P. Kissinger. 2003. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J. Acquir. Immune Defic. Syndr. 34:407-414.
18. Petry, A. S., L. A. Wenning, M. Laethem, M. De Smet, J. T. Kost, S. Merschman, K. Strohmaier, S. Ramael, K. Lasseter, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto. 2006. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects, abstr. A-376, p. 8. Abstr. Intersci. Conf. Antimicrob. Agents Chemother.
19. Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
20. Shet, A., L. Berry, H. Mohri, S. Mehandru, C. Chung, A. Kim, P. Jean-Pierre, C. Hogan, V. Simon, D. Boden, and M. Markowitz. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41:439-446.
21. Taburet, A. M., C. Piketty, C. Chazallon, I. Vincent, L. Gérard, V. Calvez, F. Gavel, J. P. Aboulker, and P. M. Girard. 2004. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreatcd human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48: 2091-2096.
22. UK Group on Transmitted HIV Drug Resistance. 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331:1368.
23. UNAIDS - Joint United Nations Programme on HIV/AIDS. 2006. Report on the global AIDS epidemic. http://www.unaids.org/en/HIV_data/2006GlobalReport /default.asp. Accessed 31 October 2007.
24. Wenning, L. A., E. Friedman, J. T. Kost, S. Merschman, K. Lasseter, N. Azrolan, K. M. Gottesdiener, J. A. Wagner, J. Stone, and M. Iwamoto. 2006. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF), abstr. A-375, p. 8. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemotherapy. American Society for Microbiology, Washington, DC.